The BOLERO-2 study demonstrated a benefit for patients who received everolimus in addition to
exemestane in patients who progressed during/after a non-steroidal aromatase inhibitor;
Routine use of everolimus shows an high rate of intolerability due to mucositis/stomatitis
especially during the first 12 weeks of treatment leading cause for treatment discontinuation
not related to tumor progression;
GeparQuinto study (setting III: non-responders): everolimus was given as salvage treatment in
combination with paclitaxel for patients without response to 4 cycles
epirubicin/cyclophosphamide with/without bevacizumab.
A dose-escalation schema was successfully used to improve tolerability of everolimus together
with the cytotoxic Agent.
Everolimus plus exemestane has improved the prognosis of metastatic breast cancer
significantly. Desiree-study aims to improve the tolerability, which is necessary in order to
achieve an adequate dose intensity for the patients in Routine care.